Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01)

Table 3 Distribution of genotypes of the investigated SNPs

SNP	Allele	N = 184 (%)	HWE χ²	P value	Call rate (%)
rs10735380	AA	110 (54.3)	2.1	0.144	94
IGF1	AG	68 (37.0)
	GG	5 (2.7)
	NE	11 (6.0)
rs1520220	CC	115 (62.5)	4.4	0.040^a	94
IGF1	CG	46 k
	GG	11 (6.0)
	NE	12 (6.5)
rs6220	AA	91 (49.5)	3.3	0.068	89
IGF1	AG	56 (30.4)
	GG	17 (9.2)
	NE	20 (10.9)
rs2946834^b	GG	82 (44.6)	10.1	0.001^a	88
IGF1	GA	53 (28.8)
	AA	26 (14.1)
	NE	23 (12.5)
rs2270628	CC	105 (57.1)	2.8	0.096	87
IGFBP3	CT	45 (24.5)
	TT	10 (5.4)
	NE	24 (13.0)
rs2854746	GG	59 (32.1)	1.9	0.170	90
IGFBP3	GC	72 (39.1)
	CC	34 (18.5)
	NE	19 (10.3)
rs4320932	TT	111 (60.3)	0.04	0.843	96
IGF2	TC	57 (31)
	CC	8 (4.3)
	NE	8 (4.3)
rs2016347	GG	48 (26.1)	1.8	0.185	96
IGF1R	GT	96 (52.2)
	TT	32 (17.4)
	NE	8 (4.3)

^aNot in HWE
^bSNP excluded from analyses because the SNP is significantly deviated from HWE after Bonferroni correction
HWE Hardy–Weinberg equilibrium, IGF insulin-like growth factor, IGFBP3 insulin-like growth factor binding protein 3, IGF1R insulin-like growth factor-1 receptor, NE Not evaluable (despite attempt to genotype), SNP single nucleotide polymorphism

ISSN: 1465-542X